StreetAlpha.app
Home › Stocks › ORKA

Oruka Therapeutics, Inc. (ORKA)

Healthcare
$95.81
▼ −1.80%
LAST CLOSE · NOV 20

Oruka Therapeutics develops antibody treatments for psoriasis and other immune and inflammatory conditions. It last closed at $95.81 on Nov 20, down 1.80% on the day. The next earnings report for ORKA is expected around Mon, Feb 8, 2027. Over its last 8 reports the stock moved an average of 3.6% the session after earnings. Over the last 12 months ORKA insiders bought $0 of stock on the open market and sold $344.6M, according to SEC Form 4 filings.

AI Auto Pilots
Is ORKA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ORKA.

Key Stats

Last 12 months
Results
Net income
−$152.6M
Free cash flow
−$123.9M
Valuation
Market cap
$6.5B
67.8M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$191.5M
At Sep 30
Shareholder equity
$1.2B
Shares outstanding
67.8M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2020: −$9.7M−$9.7MFY2020FY2021: −$19.3M−$19.3MFY2021FY2022: −$9.9M−$9.9MFY2022FY2023: −$5.3M−$5.3MFY2023FY2025: −$105.4M−$105.4MFY2025

From ORKA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Feb 8
Estimated date · Time not announced
Reported EPS
—
Not on file yet
Year ago EPS
—
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $2.21Dec '24Mar 2025: -$0.40Mar '25Jun 2025: -$0.46Jun '25Latest -$0.46
Revenue by quarter
Not enough quarters on file yet.
How ORKA moved after its last 8 reports
Average move the session after a report ±3.6%
Aug 10, 2026Time not announced+6.4%
Apr 30, 2026After the close−8.5%
Sep 5, 2024After the close+2.8%
Aug 1, 2024After the close+5.1%
Apr 25, 2024After the close+2.9%
Feb 1, 2024After the close+2.5%
Oct 18, 2023After the close−0.5%
Jul 21, 2023After the close−0.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ORKAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ORKA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ORKA

Technical Analysis

ORKA · as of the Nov 20 close · updated each morning
Uptrend

The stock sits between its 20 and 50 day averages. It is 23% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 50). The nearest support is the swing low (Aug 10) at $95.50, and the nearest resistance the swing high (Jul 20) at $96.27.

Short trendBullish
Long trendBullish
MomentumFading
StretchNormal
VolatilityNormal, 5.9%/day
Key levels
$115.5252 week high+20.6%
$99.3620 day average+3.7%
$97.60Pivot R1+1.9%
$96.27Swing high (Jul 20)+0.5%
$95.81Last close
$95.50Swing low (Aug 10)−0.3%
$95.45Pivot−0.4%
$93.66Pivot S1−2.2%
$92.72100 day average−3.2%
$90.1250 day average−5.9%
$74.24200 day average−22.5%
$25.2352 week low−73.7%
Indicators
RSI (14)50.05Middle of its rangeNeutral
MACD2.73Below its signal lineBearish
Stochastic13.3Near the bottom of its rangeOversold
ADX (14)28.2Trending up
Williams %R-87.4Oversold below −80, overbought above −20Oversold
CCI (20)-65.1Oversold below −100, overbought above 100Neutral
Rate of change−6.8%Change over 10 sessionsBearish
ATR (14)$5.67Typical daily range, 5.9% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for ORKA

What happened before

See how ORKA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ORKA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ORKA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2009.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ORKAHow many large options trades hit ORKA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

ORKA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲156 buying vs 113 selling
  • ▲Held by funds +3.8 pts
  • ●Funds holding +2
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding259257+0.8%
In funds' top 10714−50.0%
Held by funds113.2%109.3%+3.8 pts
New / increased38 / 11896 / 94−17.9%
Reduced / sold out77 / 3647 / 27+52.7%
Put/call ratio1.461.00+45.9%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ORKA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ORKA Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$344.6M47 sales · 8 insiders
13% of the selling was under pre-arranged trading plans.
2025-12 sold $214K2026-01 sold $594K2026-02 sold $227K2026-03 sold $623K2026-04 sold $463K2026-05 sold $7.6M2026-06 sold $4.0M2026-07 sold $301.9M2026-08 sold $7.5M2026-09 sold $10.4M2026-10 sold $4.1M2026-11 sold $6.9MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 20Paul T QuinlanGeneral CounselSale plan9,000$94.89$854K
Nov 16Joana GoncalvesChief Medical OfficerSale plan7,000$100.96$707K
Nov 12Kristine M BallDirectorSale plan18,000$104.93$1.9M
Nov 12Arjun AgarwalSenior Vice President, FinanceSale plan10,000$104.97$1.0M
Nov 2Lawrence Otto KleinCEOSale plan25,000$95.61$2.4M
Oct 20Paul T QuinlanGeneral CounselSale plan9,000$78.53$707K
Every insider buy and sale for ORKA over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ORKA insider trades →

From SEC Form 4 filings by ORKA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ORKA is in one of them and how their past ORKA trades turned out.

ORKA in the AI portfolios
Loading…

ORKA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ORKA in an article yet. Here's the latest on the wider market.

ORKA in the news

About Oruka Therapeutics

Oruka Therapeutics is a biopharmaceutical company based in Menlo Park, California. It is developing antibody treatments for psoriasis, a chronic skin disease, along with other immune and inflammatory conditions such as hidradenitis suppurativa and psoriatic arthritis. Its lead candidates are designed to act on IL-23 and IL-17 signaling. The company's products are still in clinical trials and not yet approved, and it aims to serve people living with these chronic skin and joint conditions.

Headquarters
Menlo Park, CA